Marie Wikström Lindholm
Chief Tech/Sci/R&D Officer chez SILENCE THERAPEUTICS PLC
Profil
Marie Wikström Lindholm is currently the Director at Oligonucleotide Therapeutics Society, Inc. since 2022.
She is also the Chief Scientific Officer at Silence Therapeutics Plc since 2017.
Previously, she worked as an Assistant Professor at the University of Lund from 1999 to 2000.
Dr. Lindholm holds a doctorate degree from the University of Uppsala.
Postes actifs de Marie Wikström Lindholm
| Sociétés | Poste | Début |
|---|---|---|
| SILENCE THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 01/12/2023 |
Oligonucleotide Therapeutics Society, Inc.
 Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The private company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Director/Board Member | 18/01/2022 |
Anciens postes connus de Marie Wikström Lindholm
| Sociétés | Poste | Fin |
|---|---|---|
| University of Lund | Corporate Officer/Principal | 01/01/2000 |
Formation de Marie Wikström Lindholm
| University of Uppsala | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SILENCE THERAPEUTICS PLC | Commercial Services |
| Entreprise privées | 1 |
|---|---|
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The private company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Commercial Services |
